AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25043197 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) 180 μg
Number of subjects: 0
Study 25043197 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) 240 μg
Number of subjects: 0
Study 23402711 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Exposure (FE)
Number of subjects: 0
Study 23402711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Exposure (ME)
Number of subjects: 0
Study 23402711 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 0
Study 21439168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS), 200 micrograms, once daily for 15 days
Number of subjects: 684
Study 21439168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study 19524176 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg/day (17 patients)
Number of subjects: 33
Study 19524176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg/day (16 patients)
Number of subjects: 33
Study 19524176 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive group pre-treatment
Number of subjects: 33
Study 17925066 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting β2-agonist (albuterol)
Number of subjects: 0
Study 17925066 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting β2-agonists
Number of subjects: 0
Study 17925066 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 14984807 — intervention group
Group type: EXPERIMENTAL
Intervention: Goûter (snack) eaters (GE)
Number of subjects: 24
Study 14984807 — intervention group
Group type: COMPARATOR
Intervention: Non-goûter snack eaters (NGSE)
Number of subjects: 24
Study 14984807 — intervention group
Group type: EXPERIMENTAL
Intervention: Goûter eaters (GE)
Number of subjects: 24
Study 14984807 — intervention group
Group type: COMPARATOR
Intervention: Non-goûter non-snack eaters (NGNSE)
Number of subjects: 24
Study 14984807 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood variables
Number of subjects: 24
Study 11521801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0
Study 11521801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9564130 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement Orientation
Number of subjects: 79
Study 9564130 — intervention group
Group type: COMPARATOR
Intervention: Control (Age-matched controls)
Number of subjects: 79
Study 9564130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study 7801759 — intervention group
Group type: COMPARATOR
Intervention: Chevron osteotomy alone
Number of subjects: 84
Study 7801759 — intervention group
Group type: EXPERIMENTAL
Intervention: Chevron osteotomy with adductor tenotomy
Number of subjects: 84
Study 7801759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 3132428 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release buccal nitroglycerin (2.5 mg, given 8-hourly)
Number of subjects: 15
Study 3132428 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 30902115 — intervention group
Group type: EXPERIMENTAL
Intervention: GHQ-28
Number of subjects: 322
Study 29051184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (20 ± 2.5 mg/kg per day for 12 months)
Number of subjects: 207
Study 29051184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 29051184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 207
Study 26475802 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid (Ringers‐acetate 20 ml kg(‐1), n=15)
Number of subjects: 30
Study 26475802 — intervention group
Group type: COMPARATOR
Intervention: Colloid (Venofundin 10 ml kg(‐1), n=15)
Number of subjects: 30
Study 23972196 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on GPs' PIPs for older patients (conducted from January 2006 to June 2006)
Number of subjects: 449
Study 23972196 — intervention group
Group type: COMPARATOR
Intervention: Another educational intervention (control group)
Number of subjects: 449
Study 21445604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy (COLD)
Number of subjects: 10
Study 21445604 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 19023851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vimala massage plus usual care
Number of subjects: 60
Study 19023851 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 17192501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet containing 15 mg of pioglitazone plus 850 mg metformin (fed state)
Number of subjects: 28
Study 17192501 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination tablet containing 15 mg of pioglitazone plus 850 mg metformin (fasted state)
Number of subjects: 28
Study 17192501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet (fed state)
Number of subjects: 28
Study 15519010 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection using the GuardWire balloon occlusion device
Number of subjects: 801
Study 15519010 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 801
Study 11314807 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Check software algorithm for CD follow-up
Number of subjects: 105
Study 11314807 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 105
Study 9727512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 24
Study 9727512 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 24
Study 9727512 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dorzolamide and latanoprost
Number of subjects: 24
Study 9727512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7804386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (225-450 mg/day)
Number of subjects: 115
Study 7804386 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (75-150 mg/day)
Number of subjects: 115
Study 3164781 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse
Number of subjects: 191
Study 3164781 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 191
Study 31799628 — intervention group
Group type: EXPERIMENTAL
Intervention: My Retainers mobile application
Number of subjects: 84
Study 31799628 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electronic reminders)
Number of subjects: 84
Study 29567664 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital Heart Assessment Tool (CHAT)
Number of subjects: 12
Study 28552240 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual heating of the radial artery
Number of subjects: 90
Study 28552240 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous nitroglycerin plus diltiazem (drug treatment group)
Number of subjects: 90
Study 25078718 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation of the occipital nerves
Number of subjects: 157
Study 24047763 — intervention group
Group type: COMPARATOR
Intervention: HUU (HIV-uninfected infants born to HIV-uninfected mothers)
Number of subjects: 0
Study 24047763 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-4a (immediate-ART, interrupted at 1 year)
Number of subjects: 0
Study 24047763 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-3 (deferred-ART)
Number of subjects: 0
Study 24047763 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-4b (immediate-ART, interrupted at 2 years)
Number of subjects: 0
Study 24047763 — intervention group
Group type: EXPERIMENTAL
Intervention: HEU (HIV-exposed uninfected)
Number of subjects: 0
Study 21962292 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp and ITNs combined
Number of subjects: 5775
Study 21962292 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp alone
Number of subjects: 5775
Study 21962292 — intervention group
Group type: EXPERIMENTAL
Intervention: ITNs alone
Number of subjects: 5775
Study 21962292 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 5775
Study 18226672 — intervention group
Group type: EXPERIMENTAL
Intervention: EAMD+OC (triphasic OC containing 180‐250 mcg norgestimate/25 mcg ethinyl estradiol)
Number of subjects: 6
Study 18226672 — intervention group
Group type: COMPARATOR
Intervention: EAMD controls
Number of subjects: 6
Study 16741261 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 degrees head-down tilt (HDT)
Number of subjects: 7
Study 16741261 — intervention group
Group type: COMPARATOR
Intervention: Upright seated (URS) posture
Number of subjects: 7
Study 14993084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.3 mg/kg, maximum 15 mg)
Number of subjects: 40
Study 14993084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14993084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40
Study 10940061 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin 910 (absorbable suture)
Number of subjects: 10
Study 10940061 — intervention group
Group type: COMPARATOR
Intervention: Nylon (nonabsorbable suture)
Number of subjects: 10
Study 9324339 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (cyclophosphamide, high-dose methotrexate, vincristine, prednisone, intrathecal chemoprophylaxis)
Number of subjects: 134
Study 9324339 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, cytarabine, coordinated intrathecal chemotherapy)
Number of subjects: 134
Study 9324339 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A
Number of subjects: 134
Study 9324339 — intervention group
Group type: COMPARATOR
Intervention: Regimen B
Number of subjects: 134
Study 8404942 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 98
Study 8404942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 3027601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (20 mg X 3)
Number of subjects: 0
Study 3027601 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg X 2)
Number of subjects: 0
Study 3027601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29433485 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma with wrist splints
Number of subjects: 41
Study 29433485 — intervention group
Group type: COMPARATOR
Intervention: Wrist splint (control)
Number of subjects: 41
Study 27872032 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering advertisements
Number of subjects: 710106
Study 27872032 — intervention group
Group type: COMPARATOR
Intervention: Nonempowering advertisements
Number of subjects: 710106
Study 27872032 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisements containing empowering content
Number of subjects: 710106
Study 27872032 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisements emphasizing health effects of smoking
Number of subjects: 710106
Study 27872032 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisements appearing at the top right of the page
Number of subjects: 710106
Study 27872032 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisements appearing at the bottom of a list
Number of subjects: 710106
Study 25101536 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 W Greenlight laser vaporization of the prostate
Number of subjects: 80
Study 25101536 — intervention group
Group type: COMPARATOR
Intervention: 80 W Greenlight laser vaporization of the prostate
Number of subjects: 80
Study 25101536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (160 W and 80 W)
Number of subjects: 80
Study 22791671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringers lactate (RL)
Number of subjects: 22
Study 22791671 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 22
Study 20531101 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence prevention program based on Latino cultural values
Number of subjects: 0
Study 20531101 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18726689 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in tooth contact via habit reversal techniques
Number of subjects: 0
Study 18726689 — intervention group
Group type: COMPARATOR
Intervention: Parafunctional activities
Number of subjects: 0
Study 15994626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active women (39% of participants)
Number of subjects: 2763
Study 15994626 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with sexual activity
Number of subjects: 2763
Study 15994626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active women (1,091 participants)
Number of subjects: 2763
Study 12842988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower expression levels of fusion transcripts at diagnosis
Number of subjects: 349
Study 12842988 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic score based on median expression ratio after consolidation therapy and 75th percentile of expression ratio at diagnosis
Number of subjects: 349
Study 12842988 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of fusion gene expression at diagnosis or less than 3 logs of tumor reduction during the first 3 to 4 months of therapy
Number of subjects: 349
Study 12842988 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels of expression during follow-up
Number of subjects: 349
Study 11053067 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week exercise
Number of subjects: 30
Study 11053067 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 11053067 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging
Number of subjects: 30
Study 8741364 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day estriol for 10 months
Number of subjects: 49
Study 8741364 — intervention group
Group type: COMPARATOR
Intervention: 1 g/day calcium lactate for 10 months (control)
Number of subjects: 49
Study 1430999 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with a cephalosporin (broad-spectrum agent)
Number of subjects: 231
Study 1430999 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (beta-lactam and aminoglycoside)
Number of subjects: 231
Study 1430999 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with a cephalosporin
Number of subjects: 231
Study 4008809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 50 mg
Number of subjects: 18
Study 4008809 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 16 mg
Number of subjects: 18
Study 4008809 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine, 50 mg
Number of subjects: 18
Study 4008809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripelennamine, 100 mg
Number of subjects: 18
Study 4008809 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine, 50 mg
Number of subjects: 18
Study 4008809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine, 16 mg
Number of subjects: 18
Study 4008809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 75 mg per day for 3 weeks
Number of subjects: 18
Study 4008809 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 24 mg per day for 3 weeks
Number of subjects: 18
Study 31403793 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) for Volume of Distribution at Steady State (VDss)
Number of subjects: 1352
Study 31403793 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) for Clearance (CL)
Number of subjects: 1352
Study 31403793 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) for Terminal Half‐Life (t1/2)
Number of subjects: 1352
Study 31403793 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) for Fraction Unbound in Plasma (fu)
Number of subjects: 1352
Study 29466591 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg haloperidol
Number of subjects: 1789
Study 29466591 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg haloperidol
Number of subjects: 1789
Study 29466591 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 1789
Study 26297029 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 32
Study 26297029 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training + Caloric Restriction (RT+CR)
Number of subjects: 32
Study 26297029 — intervention group
Group type: COMPARATOR
Intervention: RT+CR
Number of subjects: 32
Study 24345204 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets with elastomeric ligature
Number of subjects: 24
Study 24345204 — intervention group
Group type: COMPARATOR
Intervention: Self-ligating brackets without elastomeric ligature
Number of subjects: 24
Study 24345204 — intervention group
Group type: COMPARATOR
Intervention: Molar bands and bonded molar tubes
Number of subjects: 24
Study 24345204 — intervention group
Group type: COMPARATOR
Intervention: Molar bonds
Number of subjects: 24
Study 22834284 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 0.75% ropivacaine and sevorane-propofol general anaesthesia
Number of subjects: 150
Study 22834284 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 0.2% ropivacaine with fentanyl (1 microg/ml) and epinephrine (2 microg/ml) via 2 epidural catheters
Number of subjects: 150
Study 22834284 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl TIVA or inhalational sevorane-fentanyl
Number of subjects: 150
Study 20605555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic compression therapy on shoulder trigger points (supraspinatus, infraspinatus, deltoid, biceps tendon)
Number of subjects: 41
Study 20605555 — intervention group
Group type: COMPARATOR
Intervention: Ischemic compression therapy on cervical and upper thoracic areas (control group)
Number of subjects: 41
Study 20605555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic compression therapy on shoulder trigger points (after crossover for control group)
Number of subjects: 41
Study 20605555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic compression therapy on shoulder trigger points
Number of subjects: 41
Study 18060612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 952
Study 18060612 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 952
Study 16170946 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtaking maneuvers in a driving simulator
Number of subjects: 0
Study 16170946 — intervention group
Group type: EXPERIMENTAL
Intervention: Closing speed adaptation
Number of subjects: 0
Study 12483184 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with streptokinase (250,000 units bolus followed by 100,000 units/hr, max 4,000,000 units)
Number of subjects: 97
Study 12483184 — intervention group
Group type: COMPARATOR
Intervention: Heparin (anticoagulation)
Number of subjects: 97
Study 12483184 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with streptokinase
Number of subjects: 97
Study 9891197 — intervention group
Group type: EXPERIMENTAL
Intervention: RW94 (5 grams administered orally after each main meal)
Number of subjects: 32
Study 9891197 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maize starch)
Number of subjects: 32
Study 9891197 — intervention group
Group type: EXPERIMENTAL
Intervention: RW94
Number of subjects: 32
Study 8193507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoallergenic diet (soy milk or hydrolyzed milk formulas for non-breast-fed; diet without cow's milk, eggs or fish for breast-fed)
Number of subjects: 120
Study 8193507 — intervention group
Group type: COMPARATOR
Intervention: Dicyclomine hydrochloride 3 mg/kg/day
Number of subjects: 120
Study 8193507 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk and hydrolyzed milk formulas
Number of subjects: 120
Study 8193507 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment (dicyclomine)
Number of subjects: 120
Study 2454355 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 10 mg carvedilol once daily for 3 to 7 days, increased to 20 mg daily if BP reduction was insufficient
Number of subjects: 31
Study 2454355 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 31
Study 28836339 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimation
Number of subjects: 113
Study 28836339 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐vessel QCA
Number of subjects: 113
Study 28836339 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D bifurcation QCA
Number of subjects: 113
Study 28836339 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D bifurcation QCA
Number of subjects: 113
Study 27875516 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months of trastuzumab treatment
Number of subjects: 2500
Study 27875516 — intervention group
Group type: COMPARATOR
Intervention: 6 months of trastuzumab treatment
Number of subjects: 2500
Study 24881311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0
Study 24881311 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate sustained release
Number of subjects: 0
Study 23987719 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic traces assessed for adherence to BUS standard operating procedure
Number of subjects: 64
Study 21574781 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained (T)
Number of subjects: 60
Study 21574781 — intervention group
Group type: COMPARATOR
Intervention: Untrained (UT)
Number of subjects: 60
Study 19881003 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal drawing-in maneuver (ADIM)
Number of subjects: 30
Study 16214284 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step Plus with total‐etch technique
Number of subjects: 20
Study 16214284 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step Plus with self‐etch technique
Number of subjects: 20
Study 16214284 — intervention group
Group type: COMPARATOR
Intervention: One‐Step with total‐etch technique
Number of subjects: 20